Introduction {#s1}
============

Hypertension (HTN) is a major risk factor for the onset and progression of cardiovascular disease (CVD) \[[@R01]\]. When patients have multiple coronary risk factors, the Japanese Society of Hypertension Guidelines for the Management of Hypertension recommend a lower blood pressure (BP) level (\< 130/80 mm Hg) in the absence of significant coronary artery stenosis in patients with CVD \[[@R01]\]. Although long-term optimal mean BP control is important for preventing the development of CVD, visit-to-visit variability (VVV) in BP has been shown to be a strong predictor of CVD and stroke independent of mean BP and other CV risk factors \[[@R02], [@R03]\]. Muntner et al also reported that higher VVV of systolic BP (SBP) is associated with an increased risk for CVD and mortality in a prospective cohort study \[[@R04]\].

Comprehensive cardiac rehabilitation (CR) with exercise training has been shown to improve the prognosis in addition to cardiac function and exercise capacity in patients with CVD \[[@R05], [@R06]\]. We previously reported that exercise training significantly reduced BP in patients with HTN through activation of the kinin-kallikrein and dopamine systems and sympathetic inactivation \[[@R07], [@R08]\].

To prevent the repeat occurrence and progression of CVD, it may be important to manage optimal VVV in BP in addition to BP control in patients with CVD through CR. Although we previously reported that a 3-month CR program improved VVV in BP \[[@R09]\], the long-term effect of CR on VVV in BP has not yet been established. In addition, it remains unclear whether CR induces a BP reduction in patients with CVD over a long term. Accordingly, the aim of this study was to determine whether comprehensive CR improves VVV in BP and induces a BP reduction in patients with CVD in a 12-month CR program.

Methods {#s2}
=======

Study population and protocol {#s2a}
-----------------------------

Twenty-two CVD patients who had ischemic heart disease (IHD), heart failure (HF), sick sinus syndrome, pulmonary embolism and/or cardiovascular surgery and who participated in a 12-month CR program and had at least six clinic visits per month to measure BP were retrospectively enrolled. All data were collected at baseline and after 12 months. The study was approved by the ethics committee of Fukuoka University Hospital (\#15-5-09). We retrospectively collected and analyzed all data using the database of Fukuoka University Hospital.

Exercise protocol {#s2b}
-----------------

The CR group participated in a supervised exercise training program at the hospital's gym at least six times a month for 12 months. The exercise intensity was chosen to be the estimated 50% of peak VO~2~ according to heart rate (HR) and Borg's scale 11 - 13 during exercise, as described elsewhere \[[@R05], [@R10]\]. Each session lasted about 1 h, beginning with a warm-up exercise for 10 min, followed by 30 min of cycling or walking at the indicated exercise intensity and 20 min of cooling down and stretching. BP and HR were measured at rest and at the end of exercise, and an electrocardiogram (Central Monitor (DS-5700), Fukuda Denshi Co. Ltd., Tokyo, Japan) and Borg's scale were recorded during exercise. All patients were routinely screened before each exercise session, such as by symptoms, HR and rhythm, electrocardiogram, BP and medication regimen. The following conditions had to be managed during exercise: angina, dysrhythmia, hypotension, HTN, dyspnea, decreased exercise tolerance and cardiac or respiratory arrest.

Measurement of BP and assessment of BP parameters {#s2c}
-------------------------------------------------

BP was determined using an automated sphygmomanometer (HEM-8723, Omron, Tokyo, Japan) after at least 5 min of rest. SBP and diastolic BP (DBP) measurements were obtained at every visit for CR for 12 months. We used the data from six clinic visits for each of the 12 months and determined VVV in both SBP and DBP and in HR expressed as a standard deviation (SD) of average SBP, average DBP and average HR.

Data collection {#s2d}
---------------

Fasting blood samples were collected at baseline and after 12 months. Patient characteristics, including medications at baseline and brain natriuretic peptide (BNP), urea nitrogen (UN), creatinine (Cr), estimated glomerular filtration rate (eGFR), sodium (Na), potassium (K), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and hemoglobinA1c (HbA1c) in blood, were assessed at baseline and after 12 months. IHD was defined as lumen diameter stenosis \> 50% in at least one major coronary artery as determined by coronary angiography and as diagnosed by old myocardial infarction. HF was assumed based on the medical history including medications and cardiac function.

Statistical analysis {#s2e}
--------------------

A statistical analysis was performed using the Stat View statistical software package (Stat View 5; SAS Institute INC., Cary, NC). Data were expressed as the mean ± SD or number (%). The significance of differences was evaluated using Wilcoxon signed-rank test or Student's *t*-test for continuous variables and the χ^2^ test for categorical variables. A value of P \< 0.05 was considered significant.

Results {#s3}
=======

Patient characteristics at baseline in all patients {#s3a}
---------------------------------------------------

The patient characteristics at baseline are shown in [Table 1](#T1){ref-type="table"}. The mean age was 70 ± 8 years and the body mass index was 24.4 ± 4.9 kg/m^2^. In addition, the percentage (%) of males, % HF and % IHD were 77%, 55% and 27%, respectively. The use of angiotensin II receptor blocker/angiotensin converting enzyme inhibitor, diuretics, calcium channel blocker (CCB) and β-blocker were 64%, 55%, 41% and 55%, respectively.

###### Patient Characteristics and Biochemical Parameters in Blood at Baseline and After 12 Months in All Patients (n = 22)

                                    Baseline           12 months          P values (baseline vs. 12 months)
  --------------------------------- ------------------ ------------------ -----------------------------------
  Age, years                        70 ± 8             \-                 \-
  Male, n (%)                       17 (77)            \-                 \-
  BMI, kg/m^2^                      24.4 ± 4.9         24.6 ± 4.5         0.498
  HTN, n (%)                        17 (77)            \-                 \-
  DL, n (%)                         16 (73)            \-                 \-
  DM, n (%)                         9 (41)             \-                 \-
  SBP/DBP, mm Hg                    139 ± 29/71 ± 13   135 ± 31/69 ± 13   0.385/0.211
  HR, bpm                           77 ± 15            73 ± 10            0.131
  LVEF, %                           58 ± 15            \-                 \-
  CVD                                                                     
    HF, n (%)                       12 (55)            \-                 \-
    IHD, n (%)                      6 (27)             \-                 \-
    Others, n (%)                   4 (18)             \-                 \-
  Medication                                                              
    ARB/ACE-I, n (%)                14 (64)            \-                 \-
    Diuretics, n (%)                12 (55)            \-                 \-
    CCB, n (%)                      9 (41)             \-                 \-
    β-blocker, n (%)                12 (55)            \-                 \-
  Biochemical parameters in blood                                         
    BNP, pg/mL                      185 ± 226          181 ± 243          0.779
    UN, mg/dL                       19 ± 8             20 ± 9             0.938
    Cr, mg/dL                       1.3 ± 1.3          1.4 ± 1.3          0.030
    eGFR, mL/min/1.73 m^2^          57 ± 16            52 ± 15            0.106
    Na, mmol/L                      139 ± 3            140 ± 3            0.650
    K, mmol/L                       4.4 ± 0.5          4.4 ± 0.5          0.480
    LDL-C, mg/dL                    89 ± 23            77 ± 18            0.307
    HDL-C, mg/dL                    45 ± 13            50 ± 13            0.028
    TG, mg/dL                       139 ± 58           129 ± 74           0.754
    HbA1c (%)                       6.5 ± 0.6          6.7 ± 1            0.208

BMI: body mass index; HTN: hypertension; DL: dyslipidemia; DM: diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; LVEF: left ventricular ejection fraction; CVD: cardiovascular disease; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker; BNP: brain natriuretic peptide; UN: urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; Na: sodium; K: potassium; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; HbA1c: hemoglobin A1c.

Biochemical parameters in blood between baseline and after 12 months in all patients {#s3b}
------------------------------------------------------------------------------------

Next, we assessed changes in biochemical parameters in blood between baseline and after 12 months ([Table 1](#T1){ref-type="table"}). There were no significant changes in BNP, UN, eGFR or K in blood between baseline and after 12 months. The levels of HDL-C and Cr showed a significant increase between baseline and after 12 months, whereas there were no changes in LDL-C, TG or eGFR between baseline and after 12 months ([Table 1](#T1){ref-type="table"}).

Time course of changes in levels of BP and VVV in BP in all patients {#s3c}
--------------------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the time course of changes in levels of BP and VVV in BP in all patients. Although there were significant time-course changes in SBP after 3 and 4 months of the CR program, there were no significant changes in SBP or DBP between 0 and 12 months. While VVV in SBP in the first month (12.1 mm Hg) was significantly lower than that in the last (12th) month (9.3 mm Hg), there was no difference in VVV in DBP between the first and 12th months. There were no significant time-course changes in HR and VVV in HR over the 12 months.

![Time courses of changes in blood pressure (BP) (a), visit-to-visit variability (VVV) in BP (b), heart rate (HR) (c) and VVV in HR (d) in all patients. \*P \< 0.05 vs. 0 months. \#P \< 0.05 vs. 1st month. SBP: systolic blood pressure; DBP: diastolic blood pressure; N.S.: not significant.](jocmr-09-345-g001){#F1}

Patient characteristics at baseline and after 12 months in controlled and uncontrolled BP groups {#s3d}
------------------------------------------------------------------------------------------------

The patients were divided into controlled (n = 10, SBP/DBP \< 140/90 mm Hg at baseline) and uncontrolled (n = 12, SBP/DBP ≥ 140/90 mm Hg at baseline) BP groups ([Table 2](#T2){ref-type="table"}). There were no differences in the patient characteristics at baseline or after 12 months between the uncontrolled and controlled BP groups, except that SBP and DBP at baseline in the uncontrolled BP group were significantly higher than those in the controlled BP group.

###### Patient Characteristics at Baseline and After 12 Months in the Controlled and Uncontrolled BP Groups

                       Controlled BP group (n = 10)   Uncontrolled BP group (n = 12)                             
  -------------------- ------------------------------ -------------------------------- ------------------------- --------------------
  Age, years           70 ± 8                         \-                               71 ± 9                    \-
  Male, n (%)          7 (70)                         \-                               10 (83)                   \-
  BMI, kg              24.2 ± 3.4                     24.6 ± 3.3                       24.5 ± 6.1                24.7 ± 5.5
  HTN, n (%)           8 (80)                         \-                               9 (75)                    \-
  DL, n (%)            8 (80)                         \-                               8 (67)                    \-
  DM, n (%)            3 (30)                         \-                               6 (50)                    \-
  SBP/DBP, mm Hg       115 ± 15/63 ± 11               118 ± 22/65 ± 11                 158 ± 21\*\*/79 ± 9\*\*   149 ± 30/73 ± 13\*
  HR, bpm              80 ± 17                        71 ± 11                          74 ± 13                   74 ± 10
  LVEF, %              57 ± 17                                                         60 ± 13                   
  CVD                                                                                                            
    HF, n (%)          6 (60)                         \-                               6 (50)                    \-
    IHD, n (%)         3 (30)                         \-                               3 (25)                    \-
    Others, n (%)      1 (10)                         \-                               3 (25)                    \-
  Medication                                                                                                     
    ARB/ACE-I, n (%)   8 (80)                         \-                               6 (50)                    \-
    Diuretics, n (%)   3 (30)                         \-                               6 (50)                    \-
    CCB, n (%)         7 (70)                         \-                               5 (42)                    \-
    β-blocker, n (%)   6(60)                          \-                               6 (50)                    \-

BMI: body mass index; HTN: hypertension; DL: dyslipidemia; DM: diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; LVEF: left ventricular ejection fraction; CVD: cardiovascular disease; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker. \*P \< 0.05 vs. at baseline in the uncontrolled group. \*\*P \< 0.01 vs. at baseline in the controlled group.

Time course of changes in levels of SBP and DBP in the controlled and uncontrolled BP groups {#s3e}
--------------------------------------------------------------------------------------------

In the uncontrolled BP groups, SBP at baseline was significantly decreased after 2, 3, 4, 5, 7, 8 and 10 months ([Fig. 2](#F2){ref-type="fig"}). In addition, DBP at baseline in the uncontrolled BP group was significantly decreased after 2, 3, 4, 7, 8, 9, 10, 11 and 12 months. On the other hand, there were no time-course changes in SBP or DBP in the controlled BP group.

![Time courses of changes in blood pressure (BP) in the controlled BP (a) and uncontrolled BP (b) groups. \*P \< 0.05, \*\*P \< 0.01 vs. 0 months. SBP: systolic blood pressure; DBP: diastolic blood pressure; N.S.: not significant.](jocmr-09-345-g002){#F2}

Patient characteristics at baseline and after 12 months in the larger (L-) and smaller (S-) VVV in SBP groups {#s3f}
-------------------------------------------------------------------------------------------------------------

The patients were divided into two groups according to the average value of VVV in SBP as a cut-off: L-VVV (n = 6) and S-VVV (n = 16) in SBP groups ([Table 3](#T3){ref-type="table"}). There were no differences in patient characteristics including SBP (153 ± 25 mm Hg (L-VVV in SBP group) vs. 133 ± 28 (S-VVV in SBP group), P = 0.145) and DBP (78 ± 13 vs. 69 ± 12 (P = 0.174)) at baseline between the L-VVV and S-VVV in SBP groups. In addition, there were no significant changes in SBP or DBP between baseline and 12 months in both the L-VVV and S-VVV in SBP groups.

###### Patient Characteristics and Biochemical Parameters in Blood at Baseline and After 12 Months in the Smaller (S-) and Larger (L-) VVV in SBP Groups

                       S-VVV in SBP group (n = 16)   L-VVV in SBP group (n = 6)                      
  -------------------- ----------------------------- ---------------------------- ------------------ ------------------
  Age, years           72 ± 7                        \-                           66 ± 10            \-
  Male, n (%)          11 (69)                       \-                           6 (100)            \-
  BMI, kg              24.9 ± 5.2                    25.0 ± 4.5                   23.0 ± 4.1         23.6 ± 4.9
  HTN, n (%)           13 (81)                       \-                           4 (67)             \-
  DL, n (%)            12 (75)                       \-                           4 (67)             \-
  DM, n (%)            6 (38)                        \-                           3 (50)             \-
  SBP/DBP, mm Hg       133 ± 28/69 ± 12              128 ± 27/67 ± 11             153 ± 25/78 ± 13   153 ± 35/75 ± 15
  HR, bpm              77 ± 16                       72 ± 9                       78 ± 10            75 ± 13
  LVEF, %              57 ± 16                       \-                           63 ± 9             \-
  CVD                                                                                                
    HF, n (%)          9 (56)                        \-                           3 (50)             \-
    IHD, n (%)         4 (25)                        \-                           2 (33)             \-
    Others, n (%)      3 (19)                        \-                           1 (17)             \-
  Medication                                                                                         
    ARB/ACE-I, n (%)   11 (69)                       \-                           3 (50)             \-
    Diuretics, n (%)   9 (56)                        \-                           3 (50)             \-
    CCB, n (%)         6 (38)                        \-                           3 (50)             \-
    β-blocker, n (%)   10 (63)                       \-                           2 (33)             \-

VVV: visit-to-visit variability; BMI: body mass index; HTN: hypertension; DL: dyslipidemia; DM: diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; LVEF: left ventricular ejection fraction; CVD: cardiovascular disease; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker.

Patient characteristics at baseline and after 12 months in the L-VVV and S-VVV in DBP groups {#s3g}
--------------------------------------------------------------------------------------------

Next, we divided the patients into two groups according to the average value of VVV in DBP as a cut-off: L-VVV (n = 8) and S-VVV (n = 14) in DBP groups ([Table 4](#T4){ref-type="table"}). Again, there were no differences in patient characteristics at baseline and after 12 months between the L-VVV and S-VVV in DBP groups.

###### Patient Characteristics at Baseline and After 12 Months in the Smaller (S-) and Larger (L-) VVV in DBP Groups

                       S-VVV in DBP group (n = 14)   L-VVV in DBP group (n = 8)                      
  -------------------- ----------------------------- ---------------------------- ------------------ ------------------
  Age, years           72 ± 7                        \-                           67 ± 9             \-
  Male, n (%)          9 (64)                                                     8 (100)            \-
  BMI, kg              23.3 ± 3.3                    23.4 ± 3.2                   26.3 ± 6.8         26.8 ± 5.8
  HTN, n (%)           10 (71)                       \-                           7 (88)             \-
  DL, n (%)            10 (71)                       \-                           6 (75)             \-
  DM, n (%)            6 (43)                        \-                           3 (38)             \-
  SBP/DBP, mm Hg       140 ± 26/72 ± 9               131 ± 32/67 ± 11             136 ± 34/71 ± 18   141 ± 29/73 ± 15
  HR, bpm              79 ± 16                       74 ± 11                      73 ± 11            71 ± 10
  LVEF, %              58 ± 16                       \-                           60 ± 13            \-
  CVD                                                                                                
    HF, n (%)          4 (29)                        \-                           2 (25)             \-
    IHD, n (%)         6 (43)                        \-                           6 (75)             \-
    Others, n (%)      4 (29)                        \-                           0 (0)              \-
  Medication                                                                                         
    ARB/ACE-I, n (%)   9 (64)                        \-                           5 (63)             \-
    Diuretics, n (%)   6 (43)                        \-                           6 (75)             \-
    CCB, n (%)         5 (36)                        \-                           4 (50)             \-
    β-blocker, n (%)   8 (57)                        \-                           4 (50)             \-

VVV: visit-to-visit variability; BMI: body mass index; HTN: hypertension; DL: dyslipidemia; DM: diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; LVEF: left ventricular ejection fraction; CVD: cardiovascular disease; HF: heart failure; IHD: ischemic heart disease; ARB: angiotensin II receptor blocker; ACE-I: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker.

Time courses of changes in VVV in BP in the L-VVV and S-VVV in BP groups {#s3h}
------------------------------------------------------------------------

[Figure 3](#F3){ref-type="fig"} shows the time courses of changes in VVV in BP in both the L-VVV and S-VVV in BP groups. As shown in [Figure 3a](#F3){ref-type="fig"}, VVV in SBP in the first month was significantly higher than those in the second, fourth, fifth, sixth, seventh, eighth, ninth, 11th and 12th months in the L-VVV in SBP group, and significantly lower than those in the third and eighth months in the S-VVV in SBP group. In addition, VVV in DBP in the first month was significantly higher than those in the second, fifth, seventh, eighth, ninth, 10th and 11th months in the L-VVV in DBP group, and significantly lower than that in the third month in the S-VVV in DBP group ([Fig. 3b](#F3){ref-type="fig"}).

![Time courses of changes in visit-to-visit variability (VVV) in systolic blood pressure (SBP) in the larger (L-) and smaller (S-) VVV in SBP groups (a) and diastolic BP (DBP) in the L-VVV and S-VVV in DBP groups (b). \*P \< 0.05, \*\*P \< 0.01 vs. 1st month.](jocmr-09-345-g003){#F3}

Discussion {#s4}
==========

This study had two major findings. First, a 12-month CR program improved VVV in BP in patients with L-VVV in BP at baseline. Second, the CR program reduced BP in patients who had BP ≥ 140/90 mm Hg at baseline.

We found that a 12-month CR program improved VVV in BP. The mechanisms of this improvement in VVV in BP with CR are not yet clear. Generally, it is considered that an increased variability of BP may be associated with atrial stiffness \[[@R11]\] and abnormal autonomic function \[[@R12]\]. Exercise training has been associated with the suppression of sympathetic nerve activity in patients with HTN \[[@R08], [@R13]\]. Such training has been shown to prevent deterioration of the arterial baroreflex control of sympathetic nerve activity in chronic HF patients \[[@R14]\]. In addition, a 20-week CR program was associated with an improvement in arterial stiffness \[[@R15]\], although it is still controversial whether CR improves atrial stiffness. A proposed mechanism is that CR with exercise training may improve atrial stiffness and reduce excessive sympathetic nerve activity in patients with CVD. Although these mechanisms should be considered in the present study, we need to confirm this observation by analyzing atrial stiffness and sympathetic nerve activity. The patients in this study had HF and IHD. Since CR is known to improve coronary risk factors and the prognosis in patients with IHD \[[@R06]\] as well as cardiac function in HF patients \[[@R08]\], the present study provides evidence that patients with IHD and/or HF may benefit from CR, probably due to an improvement of VVV in BP.

In this study, 12 of the 22 patients changed the doses and/or kinds of anti-hypertensive medications during the study period. Although we do not know whether each antihypertensive drug affects the variability in BP to the same extent, the variability in BP is reduced by CCBs, reduced slightly less by diuretics, and increased by β-blockers, which explains the presence of class differences in the effects of drugs on stroke risk in randomized controlled trials \[[@R16], [@R17]\]. CCBs have been shown to reduce the interindividual variability in SBP when used in combination with another agent, and a smaller reduction is seen with diuretics \[[@R18]\]. It is also important to better understand the dose-response effects of each anti-hypertensive drug. Higher doses of CCBs have been shown to reduce SBP variability \[[@R18]\]. Although the class differences and dose-response effects of anti-hypertensive drugs may influence VVV in BP, we found that a 12-month CR program improved VVV in BP.

In this study, CR significantly decreased BP in patients who had BP ≥ 140/90 mm Hg at baseline, although there were no significant changes in BP between baseline and 12 months in all patients. This is a reasonable finding because patients who had BP \< 140/90 mm Hg at baseline did not need to decrease their BP. A decrease in BP with exercise training is a well-recognized phenomenon in patients with chronic HF and HTN \[[@R07], [@R08], [@R13], [@R19]\]. Exercise training is also recommended to lower BP in patients with HF \[[@R20]\]. In addition, aerobic exercise promotes a decrease in percentage body fat, decreases TG levels, and increases HDL cholesterol while reducing BP \[[@R21], [@R22]\].

The present study has several limitations. First, it was retrospective and from a single center with a relatively small sample size. Second, we did not confirm an improvement in atrial stiffness or sympathetic nerve activity. Third, each patient received different doses and kinds of medications. Therefore, a large study is needed to confirm that CR improves VVV in BP.

In conclusion, comprehensive CR program may improve VVV in SBP in CVD patients who have a larger VVV in SBP.
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